Pre-Market Movers: Altera (ALTR), Oncothyreon Inc (ONTY), ImmunoGen (IMGN), Advaxis (ADXS)

Shares of Altera Corp (ALTR) rose 6% to $51.87 this morning on news chipmaker giant Intel (INTL) has agreed to buy the company for $54 a share, or about $16.7 billion, in an all-cash deal.

Intel said that it plans to fund the acquisition, which is expected to close within six to nine months, with a combination of cash from the balance sheet as well as debt. Intel expects the deal to be accretive to its non-GAAP EPS and free cash flow in the first year after close.

Both boards have approved the transaction.

Shares of Oncothyreon Inc (ONTY) were up more than 25% this morning after the presentation of positive data from the company’s ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor for the treatment of breast cancer, at the American Society of Clinical Oncology [ASCO] 2015 Annual Meeting.

Shares of ImmunoGen, Inc. (IMGN) were up nearly 26% in pre-market hours after the company announced the presentation at the 2015 ASCO Annual Meeting of the first clinical findings in a disease-specific patient population with the company’s unique, FRα-targeting ADC, mirvetuximab soravtansine (abstract #5518). ImmunoGen said its Mirvetuximab Soravtansine (IMGN853) demonstrates notable single agent activity for patients with Platinum-Resistant ovarian cancer.

“These initial clinical findings with mirvetuximab soravtansine in the treatment of patients with FRα-positive platinum-resistant ovarian cancer are highly encouraging,” commented Dr. Kathleen Moore, Mai Eager Anderson Chair of Cancer Clinical Trials, Stephenson Cancer Center, University of Oklahoma HSC. “There is a significant need for new therapies for patients with ovarian cancer, including platinum-resistant disease.”

Shares of Advaxis, Inc. (ADXS) are higher by 3.30% to $25.99 in pre-market trading on Monday. The company announced FDA clearance of investigational new drug application for phase 2 study of ADXS-HPV.

“We are very pleased that the IND for this Phase 2 study has been cleared by the FDA,” said in a statement Rich Levy, MD, Chief Drug Development Officer at Incyte. “Epacadostat is currently in multiple combination proof-of-concept trials with immune checkpoint inhibitors, and this new study may provide us with important translational data for epacadostat in combination with an immunotherapeutic vaccine.”

Be the first to comment

Leave a Reply

Your email address will not be published.